Merck announced the U.S. FDA has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer. The approval is based on data from the Phase 3 KEYNOTE-A18 trial, in which KEYTRUDA plus CRT demonstrated an improvement in progression-free survival, reducing the risk of disease progression or death by 41% compared to placebo plus CRT in patients with FIGO 2014 Stage III-IVA disease. Median PFS was not reached in either group. This approval marks the third indication for KEYTRUDA in cervical cancer and the 39th indication for KEYTRUDA in the U.S.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Biotech Alert: Searches spiking for these stocks today
- Unusually active option classes on open January 11th
- FDA warned Merck drug could induce ‘despair,’ many weren’t told, NY Times says
- Medicenna Therapeutics commences ABILITY-1 study
- Harpoon Therapeutics downgraded to Neutral from Buy at H.C. Wainwright